Second generation BCR-ABLi such as nilotinib, dasatinib and bosutinib, are used in the treatment of CML patients with certain mutations in the ABL gene, but can be inefficient in cells carrying the gatekeeper T315I mutation [7]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.